Systematic review of available evidence on 11 high-priced inpatient orphan drugs

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Kanters, Tim A ^a   De Sonneville Koedoot, Caroline ^a   Redekop, W Ken ^a   Hakkaart, Leona ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Budget impact; Clinical effectiveness; Cost effectiveness; Evidence based medicine; Orphan drugs; Rare diseases

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALEMTUZUMAB; CANAKINUMAB; CLOFARABINE; ECULIZUMAB; FLUDARABINE; GALSULFASE; IDURONATE 2 SULFATASE; LARONIDASE; OFATUMUMAB; ORPHAN DRUG; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; TRABECTEDIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CASE STUDY; CHRONIC LYMPHATIC LEUKEMIA; CINCA SYNDROME; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG APPROVAL; DRUG COST; EVIDENCE BASED MEDICINE; FABRY DISEASE; HOSPITAL PATIENT; HUMAN; MUCOPOLYSACCHARIDOSIS; OBSERVATIONAL STUDY; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; QUALITY ADJUSTED LIFE YEAR; QUASI EXPERIMENTAL STUDY; SOFT TISSUE SARCOMA; SYSTEMATIC REVIEW; COST BENEFIT ANALYSIS; DRUG MANUFACTURE; ECONOMICS; NETHERLANDS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASES; STANDARDS;

COST-BENEFIT ANALYSIS; HUMANS; INPATIENTS; NETHERLANDS; ORPHAN DRUG PRODUCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES;

EID: 84881540834     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-124     Document Type: Article

References (30)

1. Evidence based medicine: what it is and what it isn't. Sackett DL, Rosenberg WM, Gray J, Haynes RB, Richardson WS, BMJ 1996 312 71 72 10.1136/bmj.312.7023.71 8555924
2. Clinical trials of orphan medicines. Buckley BM, Lancet 2008 371 2051 2055 10.1016/S0140-6736(08)60876-4 18555919 (Pubitemid 351799863)
3. Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. Luisetti M, Balfour-Lynn IM, Johnson SR, Miravitlles M, Strange C, Trapnell BC, Van Bronswijk H, Vogelmeier C, Respir Med 2012 106 759 768 10.1016/j.rmed.2012.02.016 22414566
4. Drugs for exceptionally rare diseases: do they deserve special status for funding? Hughes DA, Tunnage B, Yeo ST, QJM 2005 98 829 836 10.1093/qjmed/hci128 16203824 (Pubitemid 41631334)
5. Rare diseases and the assessment of intervention: what sorts of clinical trials can we use? Wilcken B, J Inherit Metab Dis 2001 24 291 298 10.1023/A:1010387522195 11405347 (Pubitemid 32479422)
6. Access to orphan drugs despite poor quality of clinical evidence. Dupont AG, Van Wilder PB, Br J Clin Pharmacol 2011 71 488 496 10.1111/j.1365-2125.2010. 03877.x 21395641
7. Systematic review of comparative effectiveness data for oncology orphan drugs. Cheng MM, Ramsey SD, Devine EB, Garrison LP, Bresnahan BW, Veenstra DL, Am J Manag Care 2012 18 47 62 22435748
8. Orphanet, Prevalence of rare diseases Paris: Bibliographic data 2011
9. Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS). Toker O, Hashkes PJ, Biologics 2010 4 131 138 20531965
10. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Moher D, Liberati A, Tetzlaff J, Altman DG, Ann Intern Med 2009 151 264 269 10.7326/0003-4819-151-4-200908180-00135 19622511
11. Randomized, controlled trials, observational studies, and the hierarchy of research designs. Concato J, Shah N, Horwitz RI, N Engl J Med. 2000 342 1887 1892 10.1056/NEJM200006223422507 10861325 (Pubitemid 30419054)
12. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Joppi R, Bertele' V, Garattini S, Eur J Clin Pharmacol 2012 69 1006 1024
13. Determinants for successful marketing authorisation of orphan medicinal products in the EU. Putzeist M, Heemstra HE, Garcia JL, Mantel-Teeuwisse AK, Gispen-De Wied CC, Hoes AW, Leufkens HG, Drug Discov Today 2012 17 352 358 10.1016/j.drudis.2011.10.027 22094244
14. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. Kesselheim AS, Myers JA, Avorn J, JAMA 2011 305 2320 2326 10.1001/jama.2011.769 21642684
15. Pivotal studies of orphan drugs approved for neurological diseases. Mitsumoto J, Dorsey ER, Beck CA, Kieburtz K, Griggs RC, Ann Neurol 2009 66 184 190 10.1002/ana.21676 19743448
16. Raising orphans: how clinical development programs of drugs for rare and common diseases are different. Orfali M, Feldman L, Bhattacharjee V, Harkins P, Kadam S, Lo C, Ravi M, Shringarpure D, Mardekian J, Cassino C, Coté T, Clin Pharmacol Ther 2012 92 262 264 10.1038/clpt.2012.87 22739137
17. The continuing unethical conduct of underpowered clinical trials. Halpern SD, Karlawish JH, Berlin JA, JAMA 2002 288 358 362 10.1001/jama.288.3.358 12117401 (Pubitemid 34761615)
18. The continuing unethical use of placebo controls. Rothman KJ, Michels KB, N Engl J Med 1994 331 394 398 10.1056/NEJM199408113310611 8028622 (Pubitemid 24233862)
19. Recombinant human acid α-glucosidase: major clinical benefits in infantile-onset Pompe disease. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Neurology 2007 68 99 109 10.1212/01.wnl.0000251268.41188.04 17151339 (Pubitemid 46071892)
20. A comparison of observational studies and randomized, controlled trials. Benson K, Hartz AJ, N Engl J Med 2000 342 1878 1886 10.1056/NEJM200006223422506 10861324 (Pubitemid 30419053)
21. Why we need observational studies to evaluate the effectiveness of health care. Black N, BMJ 1996 312 1215 1218 10.1136/bmj.312.7040.1215 8634569 (Pubitemid 26136714)
22. The problems of clinical trials and registries in rare diseases. Luisetti M, Campo I, Scabini R, Zorzetto M, Kadija Z, Mariani F, Ferrarotti I, Respir Med 2010 104 42 S44 20413285
23. Rare essentials: drugs for rare diseases as essential medicines. Stolk P, Willemen MJC, Leufkens HGM, Bull World Health Organ 2006 84 745 751 10.2471/BLT.06.031518 17128345 (Pubitemid 44482401)
24. Adopting an orphan. Rinaldi A, EMBO Rep 2005 6 507 510 10.1038/sj.embor.7400450 15940282 (Pubitemid 40973956)
25. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Sidman M, Kakkis ED, Pediatrics 2009 123 229 240 10.1542/peds.2007-3847 19117887
26. Agalsidase-beta therapy for advanced Fabry disease. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Ann Intern Med 2007 146 77 86 10.7326/0003-4819-146-2-200701160- 00148 17179052 (Pubitemid 351640010)
27. Long-term intravenous treatment of Pompe disease with recombinant human α-glucosidase from milk. Van den Hout JMP, Kamphoven JHJ, Winkel LPF, Arts WFM, De Klerk JBC, Loonen MCB, Vulto AG, Cromme-Dijkhuis A, Weisglas-Kuperus N, Hop W, Van Hirtum H, Van Diggelen OP, Boer M, Kroos MA, Van Doorn PA, Sibbles B, Van Corven EJJM, Brakenhoff JPJ, Van Hove J, Smeitink JAM, De Jong G, Reuser AJJ, Van der Ploeg AT, Pediatrics 2004 113 448 e457 10.1542/peds.113.5.e448 15121988
28. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, Meldgaard Lund A, Malm G, Van der Ploeg AT, Zeman J, Eur J Pediatr 2008 167 267 277 10.1007/s00431-007-0635-4 18038146
29. Assessing the economic challenges posed by orphan drugs. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J, Int J Technol Assess Health Care 2007 23 36 42 17234015 (Pubitemid 46648298)
30. Schey C, Milanova T, Hutchings A: Estimating the budget impact of orphan medicines in Europe: 2010-2020. Orphanet J Rare Dis 2011, 6:62.